ZS named a Leader in 2026 IDC MarketScape for Life Sciences R&D Strategic Consulting

ZS has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D Strategic Consulting Services 2026 Vendor Assessment (IDC #US53009826, May 2026). We believe this report is especially important as the life sciences industry shifts from AI experimentation to real-world impact of an intelligent enterprise.

SOURCE: IDC MarketScape: Worldwide Life Sciences R&D Strategic Consulting Services 2026 Vendor Assessment, May 2026, IDC #US53009826.

IDC MarketScape criteria selection, weightings, and vendor scores represent well researched IDC judgment about the market and specific vendors. IDC analysts tailor the range of standard characteristics by which vendors are measured through structured discussions, surveys, and interviews with market leaders, participants, and end users. Market weightings are based on user interviews, buyer surveys, and the input of IDC experts in each market. IDC analysts base individual vendor scores, and ultimately vendor positions on the IDC MarketScape, on detailed surveys and interviews with the vendors, publicly available information, and end-user experiences in an effort to provide an accurate and consistent assessment of each vendor’s characteristics, behavior, and capability.

Why ZS was named a Leader in the IDC MarketScape

Here are seven of ZS’s strengths, according to the report:

1. In silico drug development to drive ROI: “ZS is investing in in silico clinical development to help pharma scale ROI and is planning on deepening engagement with R&D domain leaders but also with enterprise IT and technology organizations to drive cross-functional transformation, and on embedding “patient-centricity” in its strategic frameworks, trial design methodologies, and evidence strategies.”
2. End-to-end perspectives and solutions: “ZS brings to the table integrated thinking and solutions spanning strategy and transformation, insights and analytics, technology, platform services, and accelerators across the life sciences value chain.”
3. Deep domain expertise: “ZS has over 250 people with advanced scientific degrees, and ZS employees have expertise in over 120 disease areas. 20% of its R&D leadership has over 15 years of R&D industry leadership experience.”
4. Asset-based differentiation: “ZS partners with over 200 pharma [companies] on R&D programs and has developed over 30 R&D technology products and accelerators, including ZAIDYN (its clinical platform for feasibility and enrollment).”
5. Agentic AI in strategic consulting: “The three key agentic AI use cases where ZS supports the life sciences industry with its strategic consulting offerings are content authoring, in silico and digital twin–driven trial design, and the use of agentic AI in clinical data management — for quality control, data standardization, transformation, and the generation of submission ready outputs.”
6. GenAI decision systems in strategic consulting: “The three key GenAI use cases where ZS supports the life sciences industry with its strategic consulting [offerings] are AI-driven clinical workflow transformation, trial design optimization, and risk based quality management.”

“Life sciences organizations are navigating increasingly complex R&D transformation challenges, as scientific innovation, data and AI reshape decision-making,” said Rohan Fernando, ZS’s managing principal for its life sciences R&D and medical practice area. “We believe this recognition in the IDC MarketScape reflects ZS’s ability to connect strategy, AI, data and technology across the full life cycle, helping clients transform ideas into impact and improve outcomes for all.”

ZS’s domain-intensive pharma R&D experience

The IDC MarketScape also noted, “The five key use cases where ZS supports its customers with its strategic consulting offering are developing AI road maps and scaling adoption, organization design, portfolio strategy, asset value maximization, and digital strategy and transformation.” The report went on to say, “Consider ZS when seeking a partner that has a strong footprint in domain-intensive areas such as global pricing and market access strategy, management consulting for pharma R&D, due diligence and asset valuation, business model innovation, M&A strategy, R&D operating model design and implementation, clinical trial budget management, clinical efficiency and productivity improvement, and predictive modeling.”

“One of ZS’s most complex strategic consulting engagements involved helping a senior, cross-functional team within a top 10 pharma to prioritize therapeutic and disease areas and pathways/MOAs for R&D and BD/M&A investment over the next decade,” the report continued. “ZS helped develop an enterprise-level portfolio strategy and a centralized decision-making framework to optimize annual capital allocation and drive toward corporate growth objectives. 25% of R&D spend was reallocated toward a focused set of programs, and shareholder returns doubled since the strategy was rolled out.”

Client perspectives from the IDC MarketScape

The report includes detailed client testimonials describing ZS’s end-to-end transformation approach:

VP, global trial optimization, of a major biopharma:

“(ZS has) created a road map for agentic AI implementation — what they are doing with agentic can change how clin ops works. Everything they do has the user lens — I think that will take our industry to a different level. When it comes to UX — they are at the forefront.”

VP of a major global pharma:

“ZS has been our partner from the inception in developing the strategy for a very large organizational transformation of about 1,000 people focused on new product development. They helped with the injection of leaders for AI readiness and helped us drive a significant shift on how this organization shows up.” Additionally, “If someone needs a partner to come up with a five-year vision, they are a good choice, to map it, and execute it more or less flawlessly— I think they are a very good partner for that. Very nice people overall — very good team members to work with — a particularly positive experience. Superior, in my experience, as compared with some of the top consulting firms.”

IDC MarketScape criteria selection, weightings and vendor scores represent well-researched IDC judgment about the market and specific vendors. IDC analysts tailor the range of standard characteristics by which vendors are measured through structured discussions, surveys, and interviews with market leaders, participants and end users. Market weightings are based on user interviews, buyer surveys and the input of IDC experts in each market.

Read an excerpt of the IDC MarketScape: Worldwide Life Sciences R&D Strategic Consulting Services 2026 Vendor Assessment (IDC #US53009826, May 2026)